Self-Contained Lateral-Flow Microfluidic Bead-Based Assay for Rapid Quantification of Early-Stage Kidney Biomarkers

Area of Science:

• Biomedical Engineering
• Clinical Diagnostics
• Biomarker Discovery

Background:

• Kidney diseases are difficult to diagnose due to complex, asymptomatic progression.
• Neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C (CysC) are key biomarkers for early kidney disease detection.
• Current NGAL and CysC quantification requires centralized laboratory analysis, limiting accessibility.

Purpose of the Study:

• To develop a rapid, self-contained diagnostic system for NGAL and CysC.
• To create a scalable platform for decentralized kidney disease biomarker analysis.
• To validate a novel assay against established methods for accuracy and efficiency.

Main Methods:

• Development of a lateral-flow microfluidic bead-based assay (LMBA) integrating microfluidic chips and paper components.
• Automated high-resolution immunoassays performed within 20 minutes.
• Validation of LMBA performance against ELISA using blood or urine samples.

Main Results:

• LMBA demonstrated comparable sensitivity and an extended dynamic range to ELISA.
• The assay requires only 1 μL of sample, with results available in 20 minutes.
• Successful application in neonatal mouse models of polycystic kidney disease, correlating biomarker levels with cyst progression.

Conclusions:

• LMBA is the first rapid, self-contained system for NGAL and CysC analysis.
• The assay's modular design offers flexibility for various applications.
• LMBA shows significant potential for decentralized kidney disease diagnostics and preclinical research.